Key facts
- This page summarizes Bernice R. Welles's Form 4 filing for SPECTRUM PHARMACEUTICALS INC.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Jun 2021, 17:53.
Bernice R. Welles - 17 Jun 2021 Form 4 Insider Report for SPECTRUM PHARMACEUTICALS INC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 17 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Kurt A. Gustafson, attorney-in-fact for Bernice R. Welles
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Bernice R. Welles filed Form 4 for SPECTRUM PHARMACEUTICALS INC on 22 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPPI
transaction
Common Stock, $0.001 par value
Award
- Transaction value
- $0
- Shares
- +14,277
- Change %
- +29%
- Price
- $0.000000
- Shares after
- 64,277
- Date
- 17 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPPI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +67,804
- Change %
- Price
- $0.000000
- Shares after
- 67,804
- Date
- 17 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 67,804
- Exercise price
- $4.29
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
100% of the restricted shares shall vest on the earlier of (1) June 17, 2022 or (2) the date of the company's 2022 Annual Meeting of Stockholders.
Footnote F2
One third of the aggregate amount of option shares shall vest on each of June 17, 2022, 2023 and 2024, respectively.